HUP9901820A3 - 4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production - Google Patents

4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production

Info

Publication number
HUP9901820A3
HUP9901820A3 HU9901820A HUP9901820A HUP9901820A3 HU P9901820 A3 HUP9901820 A3 HU P9901820A3 HU 9901820 A HU9901820 A HU 9901820A HU P9901820 A HUP9901820 A HU P9901820A HU P9901820 A3 HUP9901820 A3 HU P9901820A3
Authority
HU
Hungary
Prior art keywords
compounds
production
pyrimidine derivatives
medicaments containing
amino pyrimidine
Prior art date
Application number
HU9901820A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996108631 external-priority patent/DE19608631A1/de
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of HUP9901820A2 publication Critical patent/HUP9901820A2/hu
Publication of HUP9901820A3 publication Critical patent/HUP9901820A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
HU9901820A 1996-03-06 1997-03-03 4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production HUP9901820A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1996108631 DE19608631A1 (de) 1996-03-06 1996-03-06 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arnzeimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19629652A DE19629652A1 (de) 1996-03-06 1996-07-23 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (2)

Publication Number Publication Date
HUP9901820A2 HUP9901820A2 (hu) 1999-09-28
HUP9901820A3 true HUP9901820A3 (en) 2001-10-29

Family

ID=26023531

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901820A HUP9901820A3 (en) 1996-03-06 1997-03-03 4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production

Country Status (19)

Country Link
EP (1) EP0885226A1 (de)
JP (1) JP2000506847A (de)
KR (1) KR19990087550A (de)
CN (1) CN1212695A (de)
AU (1) AU710274B2 (de)
BG (1) BG102708A (de)
BR (1) BR9708312A (de)
CA (1) CA2243994A1 (de)
CZ (1) CZ281798A3 (de)
DE (1) DE19629652A1 (de)
EE (1) EE9800277A (de)
HU (1) HUP9901820A3 (de)
IL (1) IL125404A0 (de)
NO (1) NO984084L (de)
NZ (1) NZ331546A (de)
PL (1) PL328771A1 (de)
SK (1) SK120598A3 (de)
TR (1) TR199801749T2 (de)
WO (1) WO1997032881A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
EP1396489A1 (de) * 1999-01-27 2004-03-10 Pfizer Products Inc. Heteroaromatische Bicyclen als anti-Krebs Mittel
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
CA2530023A1 (en) 2003-06-24 2004-12-29 Neurosearch A/S Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2598489A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
MX2011004824A (es) 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
EA201100879A1 (ru) * 2008-12-01 2012-01-30 Мерк Патент Гмбх Производные пиридопиримидина в качестве ингибиторов аутотаксина
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2408479A1 (de) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Kombinationskrebstherapie mit verabreichung eines egfr-hemmers und eines igf-1r-hemmers
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
EP2468883A1 (de) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
EP2492688A1 (de) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CA2845179A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
AU2012321248A1 (en) 2011-09-30 2014-04-24 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
RU2739942C2 (ru) 2014-12-24 2020-12-30 Дженентек, Инк. Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
US11045484B2 (en) 2018-05-04 2021-06-29 Amgen Inc. KRAS G12C inhibitors and methods of using the same
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3790886A1 (de) 2018-05-10 2021-03-17 Amgen Inc. Kras-g12c-hemmer zur behandlung von krebs
MA52765A (fr) 2018-06-01 2021-04-14 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
MX2020012261A (es) 2018-06-12 2021-03-31 Amgen Inc Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
AU2019384118A1 (en) 2018-11-19 2021-05-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3123044A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US20220056015A1 (en) 2018-12-20 2022-02-24 Amgen Inc. Kif18a inhibitors
CR20210387A (es) 2018-12-20 2021-08-19 Amgen Inc Inhibidores de kif18a
JP2022514268A (ja) 2018-12-20 2022-02-10 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
SG11202109036WA (en) 2019-03-01 2021-09-29 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
SG11202112855WA (en) 2019-05-21 2021-12-30 Amgen Inc Solid state forms
CN114401953A (zh) 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
CA3147451A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
US20220372018A1 (en) 2019-08-02 2022-11-24 Amgen Inc. Kif18a inhibitors
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
CN115873020A (zh) 2019-11-04 2023-03-31 锐新医药公司 Ras抑制剂
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicíclicos y usos de estos.
AU2020383535A1 (en) 2019-11-14 2022-05-05 Amgen Inc. Improved synthesis of KRAS G12C inhibitor compound
AU2020381492A1 (en) 2019-11-14 2022-05-26 Amgen Inc. Improved synthesis of KRAS G12C inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4087611A1 (de) 2020-01-07 2022-11-16 Revolution Medicines, Inc. Shp2-inhibitordosierung und verfahren zum behandeln von krebs
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
EP4208261A1 (de) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Verwendung von sos1-inhibitoren zur behandlung von malignitäten mit shp2-mutationen
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
KR20240004960A (ko) 2021-05-05 2024-01-11 레볼루션 메디슨즈, 인크. Ras 억제제
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE4431867A1 (de) * 1994-09-07 1996-03-14 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CA2243994A1 (en) 1997-09-12
JP2000506847A (ja) 2000-06-06
IL125404A0 (en) 1999-03-12
EP0885226A1 (de) 1998-12-23
KR19990087550A (ko) 1999-12-27
AU710274B2 (en) 1999-09-16
NO984084D0 (no) 1998-09-04
BR9708312A (pt) 1999-08-03
DE19629652A1 (de) 1998-01-29
SK120598A3 (en) 1999-06-11
HUP9901820A2 (hu) 1999-09-28
BG102708A (en) 1999-09-30
PL328771A1 (en) 1999-02-15
NO984084L (no) 1998-09-04
CN1212695A (zh) 1999-03-31
EE9800277A (et) 1999-02-15
CZ281798A3 (cs) 1999-02-17
NZ331546A (en) 2000-03-27
TR199801749T2 (xx) 1998-12-21
AU1925197A (en) 1997-09-22
WO1997032881A1 (de) 1997-09-12

Similar Documents

Publication Publication Date Title
HUP9901820A3 (en) 4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production
HUP9901535A3 (en) Aryl pyrimidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP0004422A3 (en) 2-aryl-8-oxohydropurine derivatives, process for producing them, medicaments containing the same
HUP0002893A3 (en) Substituted quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP9700344A2 (en) Substituted quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP9904521A3 (en) Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9902850A3 (en) Quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0000068A3 (en) Process for producing ecteinascidin compounds, their use and pharmaceutical compositions containing them
HUP0002718A3 (en) Piperazine derivatives, process for their preparation and medicaments containing the same
HUP0102554A3 (en) Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
HUP0001115A3 (en) Heterocyclylmethyl-substituted pyrazol derivatives, process for their preparation and pharmaceuticals containing the same
HUP9802323A3 (en) Pyrimidine derivatives , process for producing them and pharmaceutical compositions containing them
HUP0003073A3 (en) Benzenesulfonamide derivatives, process for producing them and their use as medicines
HUP0001802A3 (en) Pyrazine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9800138A3 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use
HUP0000941A3 (en) Sulfamide derivatives, process for producing them, pharmaceutical compositions containing them and their use
AU8627898A (en) Pyrimidin-2,4,6-trion derivatives, method for producing the same and medicinal products containing these compounds
HUP9901739A3 (en) Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them
HUP0104033A3 (en) 1-benzoyl-tetrahydropyridazine derivatives, process for their preparation, their use and medicaments containing the compounds
HUP0104620A3 (en) 2-phenylpyran-4-one derivatives, process for their preparation and medicaments containing them
HUP0103303A3 (en) Imidazole compounds, process for producing them, their use and medicaments containing them
HUP9903902A3 (en) Bromotiacumicin compounds, process for producing them and medicaments containing the same
HUP9701921A3 (en) Heterocyclic amino-methyl compounds, process for producing them, and pharmaceutical compositions containing them
HUP0003766A2 (en) Isoguinolin derivatives, process for producing them and pharmaceutical compositions containing them
HUP0004457A3 (en) Angiogenesis inhibiting thiadiazolyl-pyridazine derivatives, process for producing them and pharmaceutical compositions containing the same